Eton Pharma founder to sell 100,000 shares

Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock that Sean E. Brynjelsen plans to sell under Rule 144.

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock that Sean E. Brynjelsen plans to sell under Rule 144. The notice lists a proposed sale of 100,000 common shares through Raymond James & Associates and discloses that 120,000 shares of common stock were sold on 05/28/2026 for about $3,826,015.00. The securities to be sold trace back to 1,000,000 founder shares acquired on 05/17/2017.

Key Figures

Proposed shares to be sold: 100000 shares Aggregate market value of proposed sale: 6343000.00 Shares sold in past 3 months: 120000 shares +3 more

6 metrics

Proposed shares to be sold 100000 shares Common stock proposed for sale through Raymond James & Associates under Rule 144

Aggregate market value of proposed sale 6343000.00 Aggregate value associated with the 100,000 common shares listed for sale

Shares sold in past 3 months 120000 shares Common stock sold by Sean Brynjelsen on 05/28/2026

Aggregate value of recent sale 3826015.00 Aggregate amount for 120,000 common shares sold on 05/28/2026

Founder shares acquired 1000000 shares Founder shares of common stock acquired from issuer on 05/17/2017

Rule 144 holding period end date 08/19/2026 Date associated with the Rule 144 securities information entry

Key Terms

Rule 144, founder shares, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

founder shares financial

"Common | 05/17/2017 | founder shares | Issuer"

Founder shares are the ownership stakes given to the people who start a company, often with extra voting power or protections compared with ordinary shares. For investors, they matter because founders’ control and incentives influence decisions about strategy, hiring, and whether the company sells or stays independent — like a family that keeps majority voting rights in a household decision. High founder ownership can mean stable leadership but also a risk that outside shareholders have less influence.

attorney-in-fact regulatory

"as attorney-in-fact for Sean E Brynjelsen"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144/A filing mean for ETON shareholders?

It reports that Sean E. Brynjelsen intends to sell 100,000 shares of Eton Pharmaceuticals, Inc. (ETON) common stock under Rule 144, and that he sold 120,000 shares on 05/28/2026 for about $3,826,015.00. It is a disclosure of potential and recent insider sales.

How many ETON shares are proposed to be sold under this Form 144/A?

The notice identifies a proposed sale of 100,000 shares of Eton Pharmaceuticals, Inc. common stock, to be handled through Raymond James & Associates as broker.

What ETON insider sold shares recently and how many?

The person identified is Sean E. Brynjelsen. During the past three months, he sold 120,000 shares of Eton Pharmaceuticals, Inc. common stock on 05/28/2026 for an aggregate amount of about $3,826,015.00.

What are the founder shares referenced in the ETON Form 144/A?

The securities to be sold are linked to founder shares of Eton Pharmaceuticals, Inc. common stock. The notice states that 1,000,000 such shares were acquired on 05/17/2017 from the issuer.

Who is acting on behalf of Sean E. Brynjelsen in the ETON Rule 144 sale?

The notice is signed by Rashida Mitchell, described as a duly authorized representative of Raymond James & Associates, Inc., acting as attorney-in-fact for Sean E. Brynjelsen in connection with the planned Rule 144 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 05:01 PM Accepted by SEC EDGAR 08/20/2026 - 05:01 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK	0001669976
Filer CCC	XXXXXXXX
Previous Accession Number Of The Filing	0001974078-26-000315
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer	Eton Pharmaceuticals, Inc.
SEC File Number	001-38738
Address of Issuer	21925 W. FIELD PARKWAY SUITE 235 DEER PARK ILLINOIS 60010-7278
Phone	(847) 787-7361
Name of Person for Whose Account the Securities are To Be Sold	BRYNJELSEN SEAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James and Associates 880 Carillon Parkway St. Petersburg FL 33716	100000	6343000.00	28583135	08/19/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/17/2017	founder shares	Issuer			1000000	05/17/2017	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sean Brynjelsen c/o Eaton Pharmaceuticals 21925 W FIELD PKWY #235 Deer Park IL 60010	Common	05/28/2026	120000	3826015.00

144/A: Remarks and Signature

Remarks
Date of Notice	08/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Sean E Brynjelsen
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)